Key facts
- This page summarizes Onaiza Cadoret-Manier's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jan 2024, 20:49.
Onaiza Cadoret-Manier - 15 Jan 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)
- Reporting relationship
- EVP, Chf GL Pdt Str & Oper Ofc
- Issuer ticker
- IONS
- Reported as of
- 15 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jan 2024, 20:49:43 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 18 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- By: Patrick R. O'Neil, attorney-in-fact For: Onaiza Cadoret-Manier
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Onaiza Cadoret-Manier filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 17 Jan 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IONS
transaction
Derivative
Performance Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +27,000
- Change %
- +94%
- Price
- $0.000000
- Shares after
- 55,635
- Date
- 15 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,000
- Exercise price
- $0.000000
- Footnotes
- F1, F2
IONS
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +32,400
- Change %
- +65%
- Price
- $0.000000
- Shares after
- 82,059
- Date
- 15 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,400
- Exercise price
- $0.000000
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
Footnote F2
The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
Footnote F3
Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
Footnote F4
Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Footnote F5
Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.